Baseline CD4+/CD8+ TEMRA Levels and Early Response Predict Survival After Umbilical Cord-Derived Mesenchymal Stem Cells Infusion in Acute GVHD Patients: A Randomized Double-Blinded Placebo-Controlled Multicentre Clinical Trial
Patients with severe grade III-IV aGVHD, particularly those who respond early or have elevated baseline CD4<sup>+</sup> T<sub>EMRA</sub> (>35%) or CD8<sup>+</sup> T<sub>EMRA</sub> (>70%) levels, may have an overall survival advantage when treated with Cyto-MSC as an upfront therapy in combination with standard corticosteroids.
Authors
- Azizan Sharif
- Soon Keng Cheong (ORCID: https://orcid.org/0000-0002-3507-6713)
- S. Chin (ORCID: https://orcid.org/0000-0003-2386-7435)
- Sharifah Shahnaz Syed Abd Kadir
- S A W Fadilah (ORCID: https://orcid.org/0000-0003-2092-7703)
- Kim Wah Ho
- Nik Syazana Saffery (ORCID: https://orcid.org/0009-0002-8860-2681)
- Sen Mui Tan (ORCID: https://orcid.org/0000-0002-3761-6752)
- Kong Yong Then
- Kian Meng Chang
Institutions
- Sultanah Aminah Hospital (MY)
- University Kebangsaan Malaysia Medical Centre (MY)
- University of Cyberjaya (MY)
- Subang Jaya Medical Centre (MY)
- KPJ Ampang Puteri Specialist Hospital (MY)
- Sunway University (MY)
- National University of Malaysia (MY)
- Universiti Tunku Abdul Rahman (MY)
Publication Details
- Journal
- Journal of Blood Medicine
- Published
- 2025-10-01
- DOI
- https://doi.org/10.2147/jbm.s546632
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universiti Tunku Abdul Rahman
- Kementerian Sains, Teknologi dan Inovasi
- Ministério da Ciência, Tecnologia e Inovação